Aastrom Receives Letter from NASDAQ (NASDAQ:ASTM)
One of the leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, Aastrom Biosciences Inc has announced that they have received a Staff Determination letter from the NASDAQ stock market which mentioned that the Company has so far not regained compliance with the $1.00 minimum losing bid price requirement as mentioned in the NASDAQ Listing Rule 5550 (a) (2). As a result, Aastrom’s common stock would be subject to delisting from the NASDAQ Capital Market on October 13, 2009 unless Aastrom Biosciences Inc requests a hearing before a NASDAQ Hearings Panel.
Aastrom Bioscience Inc has intended to request an oral hearing before the Panel within the timeframe provided by the NASDAQ, to avoid the delisting of the Company’s securities. Also, Aastrom has decided to request continued listing on the NASDAQ Capital Market based upon its plan for regaining compliance with the minimum bid price requirement. The Panel has the authority to grant Aastrom up to an additional 180 days from the date of Staff Determination letter to implement its plan of compliance. NASDAQ has further provided guidance to Aastrom stating that they will schedule the hearing within 45 days of the date of request filed by Aastrom.

By Mike Brown on 10/08/2009 7:00 am PST -- Biotech